围手术期度洛西汀对有抑郁症状的全髋关节置换术患者具有显著镇痛获益:一项随机对照试验
本研究纳入67例HAMD≥8分、拟行初次单侧全髋关节置换术的患者,随机分为度洛西汀组(每日60 mg,手术日至术后第6天)与安慰剂组,评估术后疼痛、吗啡消耗、髋关节功能及不良事件。结果显示度洛西汀组术后第3天至第3周行走及屈髋VAS评分显著更低,术后第3天至第2周静息VAS更低,吗啡消耗更少,髋关节功能评分更优,住院时间和不良事件无显著差异。
要点
- 度洛西汀组术后第3天至第3周行走及屈髋VAS评分显著低于安慰剂组。
- 度洛西汀组术后第3天至第2周静息VAS评分显著低于安慰剂组。
- 度洛西汀组吗啡消耗更少,髋关节功能评分更优,住院时间和不良事件无显著差异。
核心结论
- 围手术期短期使用度洛西汀在减少疼痛、降低吗啡消耗和改善髋关节功能方面对有抑郁症状的全髋关节置换术患者具有优势。
研究设计与样本
- 随机对照试验,从263例拟行初次单侧全髋关节置换术的患者中纳入67例17项汉密尔顿抑郁量表(HAMD)评分至少8分的患者。
- 患者随机分为度洛西汀组(每日60 mg,从手术日至术后第6天)或安慰剂组。
主要发现
- 度洛西汀组术后第3天至第3周行走及屈髋VAS评分显著低于安慰剂组。
- 度洛西汀组术后第3天至第2周静息VAS评分显著低于安慰剂组。
- 度洛西汀组吗啡消耗少于安慰剂组。
- 度洛西汀组髋关节活动度、Harris髋关节评分(HHS)和WOMAC功能评分优于安慰剂组。
- 两组住院时间和不良事件无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major symptoms of depression are commonly observed in patients requiring total hip arthroplasty (THA), and this is associated with increased pain scores and opioid consumption. We aimed to investigate the analgesic effect of duloxetine in these high-risk patients. METHODS: Among 263 patients scheduled for primary unilateral THA, 67 patients who scored at least 8 on the 17-item Hamilton Depression Scale (HAMD) were enrolled in this study. Patients were randomized to the duloxetine group (60 mg daily, from the day of surgery to postoperative day 6) or the placebo group. The postoperative visual analog scale (VAS) score during walking, the VAS score during hip flexion, and resting VAS score was measured. Postoperative morphine consumption, hip range of motion (ROM), Harris hip score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function, postoperative length of stay (LOS), and adverse events were recorded. RESULTS: The duloxetine group had significantly lower VAS scores during walking and hip flexion from postoperative day 3 to week 3 than the placebo group. With regard to the resting VAS score, duloxetine showed a better analgesic effect from postoperative day 3 to week 2 than placebo. Patients in the duloxetine group had less consumption of morphine. The duloxetine group exhibited better hip function scores, including ROM, HHS, and WOMAC function scores than the placebo group. No significant difference was observed in LOS or adverse events between groups. CONCLUSION: Perioperative short-term duloxetine provides advantages in decreasing pain, reducing morphine consumption, and increasing hip function in THA patients who have depressive symptoms.
引用
- Ding ZC, Li H, Huang C, et al. Significant Analgesic Benefits of Perioperative Duloxetine in Patients Who Have Depressive Symptoms Undergoing Total Hip Arthroplasty: A Randomized Controlled Trial. J Arthroplasty. 2022. PMID: 36252745. doi:10.1016/j.arth.2022.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。